Results 111 to 120 of about 459,966 (302)

Three cases of herpes zoster radiculitis in MS patients treated with natalizumab [PDF]

, 2016
Natalizumab was the first FDA-approved monoclonal antibody for the treatment of multiple sclerosis (MS). We report on 3 natalizumab-treated patients who developed herpes zoster infections.
Khoury, Samia J., Yamout, Bassem I., Zeineddine, Maya M., Taha, Ali J., Abou-Zeid, Nuhad E.   +4 more
core   +1 more source

The impact of social and environmental factors on triggering multiple sclerosis onset, before and during the COVID-19 pandemic: a retrospective study from Iran

BMC Neurology
Background Multiple sclerosis (MS) is a chronic, inflammatory, and demyelinating disease of the central nervous system. The first presentation’s possible triggers are still controversial among scientists. The objective of this study is to investigate and
Naghmeh Abbasi Kasbi, Fereshteh Ghadiri, Abdorreza Naser Moghadasi, Faezeh Khodaie, Kosar Kohandel, Nasim Rezaeimanesh, Maryam Karaminia, Mohammad Ali Sahraian   +7 more
doaj   +1 more source

ALDOA Promotes Glycolysis and NLRP3/GSDMD Pyroptosis to Accelerate ALS Progression

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Amyotrophic lateral sclerosis (ALS) is characterized by progressive motor neuron degeneration. Glycolytic dysregulation is implicated in disease progression, yet the underlying mechanisms remain unclear. This study investigates how Aldolase A (ALDOA) drives ALS progression through glycolysis‐mediated motor neuron pyroptosis.
Kaixin Yan, Yan Jiang, Yuxuan Yong, Tianshuo Zhang, Niannian Zhang, Qianqian Zeng, Xue Gong, Li Meng, Fangfang Bi, Yongmin Liu   +9 more
wiley   +1 more source

The patient perspective of living with Multiple Sclerosis : the Swiss Database of Patients‘ Narratives [PDF]

, 2018
Introduction: Listening to patients’ voices is increasingly being recognized as an important factor for continuous improvement in health care. Integrating patients’ stories about their experiences with multiple sclerosis (MS) seems paramount considering ...
Glässel, Andrea, Hendriks, Manya, Biller-Andorno, Nikola, Petry, Heidi, Streeck, Nina, Kesselring, Jürg   +5 more
core   +2 more sources

[18F]Fluorodeprenyl‐D2 PET as a Tool to Monitor Disease Activity in GAD65‐Ab Autoimmune Encephalitis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate [18F]fluorodeprenyl‐D2 ([18F]F‐DED) positron‐emission tomography (PET) imaging as a biomarker of disease activity in autoimmune encephalitis (AIE) associated with glutamic acid decarboxylase 65 (GAD65) antibodies. Methods [18F]F‐DED PET was performed in 25 GAD65‐AIE patients and 8 controls using dynamic (0–60 min) and ...
Julia S. Dorneich, Jonathan A. Gernert, Hanna Zimmermann, Lisa Tagnin, Marianthi Zeinaki, Laura Sanzo, Letizia Vogler, Elisabeth Kaufmann, Justina Dargvainiene, Frank Leypoldt, Gérard N. Bischof, Robert Perneczky, Boris‐Stephan Rauchmann, Simon Lindner, Günter U. Höglinger, Rudolf A. Werner, Martin Kerschensteiner, Tania Kümpfel, Matthias Brendel, Franziska S. Thaler   +19 more
wiley   +1 more source

No evidence of a significant role for CTLA-4 in multiple sclerosis [PDF]

, 2006
Variation in the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) gene plays a significant role in determining susceptibility to autoimmune thyroid disease and type 1 diabetes. Its role in multiple sclerosis is more controversial. In order to explore
Maranian, M, Hensiek, A, Sawcer, S, Roxburgh, R, Seaman, S, Compston, A, Yeo, T, Deans, J   +7 more
core  

GAD65 Antibody ELISA With Extended Reportable Range: Validation and Guidance for Neurological Practice

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To (1) validate GAD65‐ELISA detection and quantification for type 1 diabetes mellitus and autoimmune neurological diagnoses, (2) correlate ELISA results (reference range < 5 IU/mL) with established radioimmunoprecipitation assay (RIA; ≤ 0.02 nmol/L), and (3) define ELISA clinical utility and pitfalls.
Andrew McKeon, Dana Olofson, Diana Anissian, Divyanshu Dubey, Eoin P. Flanagan, Max C. Herman, Sarosh R. Irani, Daniel H. Lachance, Maria A. Willrich, Sean Pittock, John R. Mills, Anastasia Zekeridou   +11 more
wiley   +1 more source

Neurofilament light as a prognostic marker in multiple sclerosis [PDF]

, 2010
Relapsing-remitting multiple sclerosis has a variable prognosis and lacks a reliable laboratory prognostic marker. Our aim in this study was to investigate the association between neurofilament light levels in cerebrospinal fluid in early multiple ...
Sundström, Peter,, Salzer, Jonatan,, Svenningsson, Anders,   +2 more
core   +1 more source

Longitudinal Assessment of Biomarkers in ALS: Discriminative Biomarkers for Disease Progression and Survival

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To assess the association and discriminative performance of serum biomarkers with clinical disease progression and survival in patients with amyotrophic lateral sclerosis (ALS). Methods This retrospective study, conducted at Houston Methodist Hospital, Houston, TX, used longitudinal serum samples collected between January 2018 and ...
David R. Beers, Yueh‐Yun Lin, Jason R. Thonhoff, Aaron D. Thome, Alireza Faridar, Weihua Zhao, Shixiang Wen, Stanley H. Appel   +7 more
wiley   +1 more source

Analysing the course of multiple sclerosis with segmented regression models [PDF]

, 2003
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system whose cause is still unknown. The disease course shows great inter- and intra-individual variability and this results in insecurity of diagnosis and prognosis.
Hellriegel, B., Neiß, A., Neiss, Albrecht, Hellriegel, Barbara, Daumer, Martin   +4 more
core   +1 more source